Ligand Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Ligand Pharma (LGND) Tops Q1 EPS by 40c
May 8, 2018 4:45 PM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.55, $0.40 better than the analyst estimate of $1.15. Revenue for the quarter came in at $56.2 million versus the consensus estimate of $43.02 million.
GUIDANCE:
Ligand Pharma sees FY2018 EPS of $4.85, versus the consensus of $4.67.
Ligand affirms... More
